HPV and Pap Testing Market Exhibits Higher Growth Prospects during 2019-2029

HPV and Pap Testing
HPV and Pap Testing

HPV is an abbreviation for human papillomavirus, which is a family of more than 150 viruses. Each HPV virus is assigned a number or a type. HPVs are only attracted to a type of cell known as squamous epithelial cells, and the viruses can only live in these cells. Some human papillomaviruses cause non-cancerous tumors, while others cause cancer, including cancer of the cervix, vagina, vulva, anus, penis, and parts of the mouth and throat that are mostly made up of moist skin in the body. This HPV and Pap Testing Market are classified as mucosal because they infiltrate living cells on mucosal surfaces. Cervical cancer can be prevented by detecting and treating abnormal cells that develop in the cervix.

The increasing prevalence of chronic diseases such as cervical and vaginal cancer is expected to drive the Growth of The HPV and Pap Testing Market. According to the National Cervical Cancer Coalition, approximately 12,000 women in the United States are diagnosed with cervical cancer each year. Furthermore, according to the American Sexual Health Association (ASHA), cervical cancer is one of the most preventable types of cancer. These cancers can be avoided by detecting and treating abnormal cell changes in the cervix prior to the development of cervical cancer cells.

Technological advancements in the diagnostics field are also expected to drive the market during the forecast period. For example, Nurx, a consumer health and telemedicine company, launched the Home HPV Screening test in January 2019. The new test enables women to check their risk of cervical cancer from the comfort of their own homes in a convenient and cost-effective manner. 

However, the inaccuracy of smear-based Pap tests, which leads to low reliability, is expected to stymie global HPV and Pap Testing Market growth. Furthermore, new product launches aimed at improving the existing accuracy of HPV testing are expected to fuel the growth of the global HPV testing and Pap test markets. For example, in June 2016, QIAGEN N.V introduced the QIAsure Methylation Test to assess the risk of developing cervical cancer.

Comments

Popular posts from this blog

Security Robot Market to Reach US$ 11.8 Billion by 2022

Intravenous Fluid Therapy is the Fastest Growing Segment Fueling the Growth of Intravenous Solutions Market

Global Report on LED Driver Market for the Forecast Period 2023-2030